Acquisition of regulatory function by human CD8(+) T cells treated with anti-CD3 antibody requires TNF.
about
Inducing and Administering Tregs to Treat Human DiseaseInduced CD8+FoxP3+ Treg cells in rheumatoid arthritis are modulated by p38 phosphorylation and monocytes expressing membrane tumor necrosis factor α and CD86.Contrasting effects of TNF and anti-TNF on the activation of effector T cells and regulatory T cells in autoimmunity.Resolving the identity myth: key markers of functional CD4+FoxP3+ regulatory T cells.Teplizumab treatment may improve C-peptide responses in participants with type 1 diabetes after the new-onset period: a randomised controlled trialImmune interventions to preserve β cell function in type 1 diabetesChanges in T-cell subsets identify responders to FcR-nonbinding anti-CD3 mAb (teplizumab) in patients with type 1 diabetesTargeting regulatory T cells in the treatment of type 1 diabetes mellitus.TNF optimally activatives regulatory T cells by inducing TNF receptor superfamily members TNFR2, 4-1BB and OX40Teplizumab preserves C-peptide in recent-onset type 1 diabetes: two-year results from the randomized, placebo-controlled Protégé trial.Teplizumab (anti-CD3 mAb) treatment preserves C-peptide responses in patients with new-onset type 1 diabetes in a randomized controlled trial: metabolic and immunologic features at baseline identify a subgroup of responders.Therapeutic polyclonal human CD8+ CD25+ Fox3+ TNFR2+ PD-L1+ regulatory cells induced ex-vivo.The phenotypic and functional consequences of tumour necrosis factor receptor type 2 expression on CD4(+) FoxP3(+) regulatory T cells.Teplizumab for treatment of type 1 diabetes mellitus.Treatment of new onset type 1 diabetes with teplizumab: successes and pitfalls in development.The impact of biological therapy on regulatory T cells in rheumatoid arthritis.Addressing Unmet Medical Needs in Type 1 Diabetes: A Review of Drugs under Development.Role of the Immune Response in Disease Progression and Therapy in Multiple Myeloma.Therapeutic anti-CD3 monoclonal antibodies: from bench to bedside.EBV infection and anti-CD3 treatment for Type 1 diabetes: bad cop, good cop?NKG2A is a marker for acquisition of regulatory function by human CD8+ T cells activated with anti-CD3 antibody.Human CD8+ regulatory T cells inhibit GVHD and preserve general immunity in humanized mice.Remodeling T cell compartments during anti-CD3 immunotherapy of type 1 diabetes.Generation and function of immunosuppressive human and murine CD8+ T cells by transforming growth factor-β and retinoic acid.The Significance of Tumor Necrosis Factor Receptor Type II in CD8+ Regulatory T Cells and CD8+ Effector T Cells.
P2860
Q26772723-4A23E56C-1962-4285-9C11-30A5079EB46BQ34427172-95F2E7DD-F14A-444C-B069-4BC23D2D44A8Q35190025-E77BEFD5-E39D-48D4-91D9-4CD945E82CCEQ35242154-36ADABCC-AA87-416F-8EF9-53BA61E7859DQ36510973-721D41D5-B670-4320-851E-3BF0E7890170Q36520618-4613835B-749C-4364-9F28-B0F7C4F6662AQ36940282-9CE8B51F-9E6C-4293-89B6-05270C648B9FQ37006155-606A72D6-6F65-49B8-8727-D838660C3D85Q37197918-BEE02129-3DEF-4959-903D-B5EADF192735Q37251132-C216F758-B129-4694-BAC2-0A4B6D1AE52EQ37251153-BB478304-B60C-4929-96F3-C77669FF5077Q37616428-D3D06E73-733B-4AB0-A551-4F0626195836Q37883460-B11421D5-66CC-4D5F-9AA3-CF1AF714B034Q38042560-1D4B81D4-4DD0-49AD-B423-CF9F531797BAQ38187146-E6BF72DA-5621-4047-91F4-B02CD38D3015Q38350483-BD88199B-2A52-447E-85BB-598337DE4815Q38806457-A0B960BF-A8A9-4D65-B985-588434626823Q38815399-2A445C26-A673-4A46-9222-39B599D1DFD9Q38830417-9090C456-113D-4CBF-8E59-CB62F41FFF1BQ41860467-636DFF35-3E6E-42F0-A22C-7E1CC0A4DB77Q42397410-CCFF055A-73B9-407E-81B0-41B45002877FQ44201994-67C7498A-0A9A-4F6F-A8BF-3F629E5A4A16Q45066081-A1868DD8-0FEE-4FAE-84BD-B52BD391E831Q50517775-410AE1A8-B49F-4424-AC4E-0E5BFE418C41Q52330488-35F7A833-2309-4894-B6F9-1F2E816E0261
P2860
Acquisition of regulatory function by human CD8(+) T cells treated with anti-CD3 antibody requires TNF.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
2010年论文
@zh
2010年论文
@zh-cn
name
Acquisition of regulatory func ...... nti-CD3 antibody requires TNF.
@en
type
label
Acquisition of regulatory func ...... nti-CD3 antibody requires TNF.
@en
prefLabel
Acquisition of regulatory func ...... nti-CD3 antibody requires TNF.
@en
P2093
P2860
P356
P1476
Acquisition of regulatory func ...... nti-CD3 antibody requires TNF.
@en
P2093
Brygida Bisikirska
Kevan C Herold
Vitaly Ablamunits
P2860
P304
P356
10.1002/EJI.201040485
P407
P577
2010-10-01T00:00:00Z